20 articles
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Scientists found that inhibiting USP30, a mitochondrial enzyme, restores immune cell function and shrinks tumors in mice.
Scientists discover KLHL6 protein prevents immune cell dysfunction in tumors, offering new target for cancer immunotherapy.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
Researchers use advanced cell profiling to develop personalized immune treatments for thyroid cancer patients.
Comprehensive review reveals how cancer cells manipulate immune recognition and promising therapeutic strategies to restore T cell immunity.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
A newly identified macrophage-Treg axis in tumor-draining lymph nodes may explain how colorectal cancer evades immune attack.
Scientists discover that enhancing protein cleanup in immune cells prevents exhaustion and dramatically improves cancer immunity.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
Harvard researchers demonstrate that activated macrophages can both trigger immune responses and infiltrate tumors directly.
